ASC - Autism Study

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 9, 2023

Primary Completion Date

June 28, 2024

Study Completion Date

September 20, 2024

Conditions
Autism Spectrum DisorderGastrointestinal DysfunctionLeaky Gut SyndromeMesenchymal Stromal CellsInflammatory Bowel Diseases
Interventions
DRUG

Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)

"The Investigational Product is a C2C\_ASC cell product (Cell2Cure®, Cell2Cure Aps, Denmark).~C2C\_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C\_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C\_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The excipient is CryoStor10 (Biolife Solutions), holding 10% DMSO."

Trial Locations (1)

Unknown

Department of Child and Adolescent Psychiatry, Psychiatry Clinic South, Aalborg University Hospital, Denmark, Aalborg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cell2Cure ApS

INDUSTRY